APC (BioDeep_00000011250)

 

Secondary id: BioDeep_00001878076

human metabolite Endogenous blood metabolite


代谢物信息卡片


7-Ethyl-10-(4-N-aminopentanoic acid)-1-piperidino)carbonyloxycamptothecin

化学式: C33H38N4O8 (618.2689508)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 5.13%

分子结构信息

SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)NCCCCC(=O)O
InChI: InChI=1S/C33H38N4O8/c1-3-21-22-15-20(45-32(42)36-13-10-19(11-14-36)34-12-6-5-7-28(38)39)8-9-26(22)35-29-23(21)17-37-27(29)16-25-24(30(37)40)18-44-31(41)33(25,43)4-2/h8-9,15-16,19,34,43H,3-7,10-14,17-18H2,1-2H3,(H,38,39)/t33-/m0/s1

描述信息

同义名列表

3 个代谢物同义名

7-Ethyl-10-(4-N-aminopentanoic acid)-1-piperidino)carbonyloxycamptothecin; Irinotecan Related Compound(RPR 121056); APC



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

3 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(1)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(2)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Giuseppe Corona, Caterina Elia, Bruno Casetta, Giuseppe Toffoli. Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype. Therapeutic drug monitoring. 2010 Oct; 32(5):638-46. doi: 10.1097/ftd.0b013e3181ec3bf5. [PMID: 20683392]
  • Fabrizio D'Esposito, Bruce N Tattam, Iqbal Ramzan, Michael Murray. A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 Nov; 875(2):522-30. doi: 10.1016/j.jchromb.2008.10.011. [PMID: 18952506]
  • Patrick A Thompson, Manish Gupta, Gary L Rosner, Alexander Yu, Jeffrey Barrett, Lisa Bomgaars, Mark L Bernstein, Susan M Blaney, John Mondick. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer chemotherapy and pharmacology. 2008 Nov; 62(6):1027-37. doi: 10.1007/s00280-008-0692-z. [PMID: 18278496]
  • Kimie Sai, Yoshiro Saito, Hiromi Fukushima-Uesaka, Koichi Kurose, Nahoko Kaniwa, Naoyuki Kamatani, Kuniaki Shirao, Noboru Yamamoto, Tetsuya Hamaguchi, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura, Yasuhide Yamada, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Jun-ichi Sawada. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer chemotherapy and pharmacology. 2008 Aug; 62(3):529-37. doi: 10.1007/s00280-007-0634-1. [PMID: 17992531]
  • Sanjay Goel, Kavita Desai, Sirisha Karri, Radharani Gollamudi, Imran Chaudhary, Anca Bulgaru, Andreas Kaubisch, Gary Goldberg, Mark Einstein, Fernando Camacho, Sharyn Baker, Sridhar Mani. Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Investigational new drugs. 2007 Jun; 25(3):237-45. doi: 10.1007/s10637-006-9028-1. [PMID: 17195945]
  • Sylvain Poujol, Frédéric Pinguet, Françoise Malosse, Cécile Astre, Marc Ychou, Stéphane Culine, Françoise Bressolle. Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. Clinical chemistry. 2003 Nov; 49(11):1900-8. doi: 10.1373/clinchem.2003.023481. [PMID: 14578322]
  • Amar Gajjar, Murali M Chintagumpala, Daniel C Bowers, Dana Jones-Wallace, Clinton F Stewart, Kristine R Crews. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer. 2003 May; 97(9 Suppl):2374-80. doi: 10.1002/cncr.11308. [PMID: 12712459]
  • M K Ma, W C Zamboni, K M Radomski, W L Furman, V M Santana, P J Houghton, S K Hanna, A K Smith, C F Stewart. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Mar; 6(3):813-9. doi: NULL. [PMID: 10741701]
  • A Sparreboom, P de Bruijn, M J de Jonge, W J Loos, G Stoter, J Verweij, K Nooter. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. Journal of chromatography. B, Biomedical sciences and applications. 1998 Aug; 712(1-2):225-35. doi: 10.1016/s0378-4347(98)00147-9. [PMID: 9698245]
  • M C Haaz, L Rivory, C Riché, L Vernillet, J Robert. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer research. 1998 Feb; 58(3):468-72. doi: NULL. [PMID: 9458091]
  • L P Rivory, M C Haaz, P Canal, F Lokiec, J P Armand, J Robert. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 Aug; 3(8):1261-6. doi: NULL. [PMID: 9815808]
  • L P Rivory, J F Riou, M C Haaz, S Sable, M Vuilhorgne, A Commerçon, S M Pond, J Robert. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer research. 1996 Aug; 56(16):3689-94. doi: . [PMID: 8706009]
  • M S Park, P I Terasaki, D Bernoco. Autoantibody against B lymphocytes. Lancet (London, England). 1977 Sep; 2(8036):465-7. doi: 10.1016/s0140-6736(77)91598-7. [PMID: 70684]